BEAM's Quality Score fell 1 point on Wed, Nov 11, to 3.
Follow BEAM's trial news. Pro members can get an alert when Beam Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 14% over three years while the S&P 500 rose 77%; up 16% in the past year.
| Holding it back | Free cash flow -$398M on $147M of sales |
| Latest filing | 8-K, Nov 3 |
Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
Expected to report Tue Feb 23, before the open
3 more dates ahead: conferences, for Pro members.
About 10 quarters
CEO John M. Evans sold 50,000 shares on Oct 16, under a planned sale. 16 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
BEAM is #92 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 92 |
Share count against a year before: BEAM +2.1%, EDIT +70%, NTLA +27%, DNLI +9.3%.
Expected to report Tue Feb 23, before the open (in 104 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.28 a share, from $1.10.
BEAM's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Beam expects to initiate dosing in the Phase 1/2 trial in early 2027.”
From its results filing (SEC filing · Nov 3)
Sales grew 32% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 16% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +1.5% | +1.8% | +4.5% |
| Aug 4, 2026 | +3.2% | +9.4% | +5.3% |
| May 7, 2026 | -1.9% | -2.7% | -1.5% |
Sales grew in five of the last six years, to $140M in 2025. It lost money in each of the seven years.
RSI 47.9, MACD below signal, below both averages. Not scored.
One insider sold $10M across 2 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BEAM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
“The pharmaceutical and biotechnology industries, including the genetic medicines field, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property.”
BEAM scores 3 today, which Breakaway calls Below Average. It is #92 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 14% over three years while the S&P 500 rose 77%; up 16% in the past year. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BEAM scores 3 today, which Breakaway calls Below Average (0 to 5). That is #92 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BEAM's 3.
One insider sold $10M across 2 filings in the last 6 months. No open-market buys on record. The newest is Fmr LLC, 10% owner, who sold $8.9M on Jun 26. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.